Navigation Links
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Date:11/22/2013

ical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012.  Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking StatementsThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regene
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Sanofi US Launches Collaborate Activate Innovation Challenge
3. Sanofi Pasteur to add 2D barcode to six more vaccines
4. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
5. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
6. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
7. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
8. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
9. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Uroplasty, Inc. (NASDAQ: UPI ), ... markets innovative proprietary products to treat voiding dysfunctions, ... first quarter ended June 30, 2014.  Global ... System grew 19% to $4.1 million, as compared ... the prior year.  Total revenue for the fiscal ...
(Date:7/24/2014)... Calif. , July 24, 2014 Amgen (NASDAQ: ... its second quarter financial results on Tuesday, July 29, 2014, ... will be followed by a conference call with the investment ... Amgen will be Robert A. Bradway , chairman and ... team. Live audio of the conference call will ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/26/2014)... July 26, 2014 Recently, iFitDress.com, a ... for women, has unveiled its new range of high ... offer on the brand new items; they are now ... , iFitDress.com is one of the leading suppliers ... officer, all the wholesale party dresses have ...
(Date:7/26/2014)... Dallas,Texas (PRWEB) July 26, 2014 “BRIC ... on the BRIC Sinuscopes market. The report provides value, ... average prices (in US dollars) within market segments – ... shares and distribution shares data for each of these ... market participants, pipeline products, and news and deals related ...
(Date:7/26/2014)... TX (PRWEB) July 26, 2014 ... or encephalomyelitis disseminata, is an inflammatory disease in ... the brain and spinal cord are damaged. This ... nervous system to communicate, resulting in a wide ... and sometimes psychiatric problems. Multiple sclerosis takes several ...
(Date:7/26/2014)... Seattle, Wa (PRWEB) July 26, 2014 ... updated by Vkool.com, this is a comprehensive bodybuilding program ... simultaneously without using anabolic steroids . The program ... lean muscle without cardio. , Vkool reveals in ... exercises and workouts that can help men get ripped ...
(Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist ... general dentistry, clear braces and much more, has just ... in Derby. The new practice, which is scheduled to ... in Littleover, Derby. Patients may already pre-register for the ... dental practice, which is headed by Invisalign specialist and ...
Breaking Medicine News(10 mins):Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2
... in small study took capsules equivalent to brewed beverage, , ... green tea might slow the progression of prostate cancer, the ... 26 men, 41 to 72 years old, who had prostate ... took four capsules a day of an investigational agent called ...
... , Local Vascular Surgeon Named National Principal Investigator , ... from Arizona Heart Institute performed the first procedure in ... Vascutek Anaconda Stent Graft System , an investigational, minimally ... , Leading the study efforts in the U.S. ...
... , DEERFIELD BEACH, Fla., June 19 Sentry Data ... scanning device, Sentinel Mobile Manager(TM), as part of ... feedback and the desire to provide increased value ... with Sentinel RCM,s(TM) core functionality and provides a ...
... BEIJING, June 19 /PRNewswire-Asia-FirstCall/ -- China ... a leading China-based medical device,company that develops, manufactures and ... financial results for,the fourth fiscal quarter (,4Q FY2008,) and ... 2009 (,FY2008,). The Company,s 2008 fiscal year ends ...
... ... readers, AmericanHealthandBeauty.com has added Dysport, formerly known as Reloxin, as a procedure on their website. ... Houston, TX (PRWEB) June ... lines and wrinkles on the face, has recently gained FDA approval and is expected to ...
... (NYSE: SRZ ) today announced that it will transition ... As previously disclosed in its 2008 10-K, Sunrise could be terminated ... to comply with their financial covenants in 2008. HCP announced ... , "While we regret the loss of these communities, it ...
Cached Medicine News:Health News:Green Tea Component May Slow Prostate Cancer 2Health News:Arizona Heart Institute Enrolls First Patient in Anaconda(TM) Investigational Study for the Treatment of Abdominal Aortic Aneurysm 2Health News:Arizona Heart Institute Enrolls First Patient in Anaconda(TM) Investigational Study for the Treatment of Abdominal Aortic Aneurysm 3Health News:Sentry Data Systems, Inc. Announces: Sentinel RCM(TM) - Now with Mobile Manager(TM) Included! 2Health News:China Medical Technologies Announces Selected Unaudited Preliminary Financial Results for the Fourth Fiscal Quarter and Full Year Ended March 31, 2009 2Health News:China Medical Technologies Announces Selected Unaudited Preliminary Financial Results for the Fourth Fiscal Quarter and Full Year Ended March 31, 2009 3Health News:Dysport Added as a Procedure on AmericanHealthandBeauty.com: Let the Wrinkle Wars Begin 2Health News:Dysport Added as a Procedure on AmericanHealthandBeauty.com: Let the Wrinkle Wars Begin 3
... Tissue transglutaminase (tTg) is a ... of proteins. Tissue transglutaminase is also ... by the endomysial antibody immunofluorescence (EMA) ... 29060). Anti-tTg IgA and IgG serologic ...
... training it needs with the NetLearning Management ... Capital Management System in one. Whether it ... and HIPAA, understanding compliance reporting for OSHA, ... through continuing education courses, the NetLearning system ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Medicine Products: